Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, ¹⁸F-FDG PET/MRI and CA 19-9.

ABSTRACT:

Background

CT prediction of resectability and prognosis following neoadjuvant treatment (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC) remains challenging. This study aims to determine whether addition of ¹⁸F-fluorodeoxyglucose (FDG) postiron emission tomography (PET)/MRI and carbohydrate antigen (CA) 19-9 to contrast-enhanced CT (CECT) can improve accuracy of predicting resectability compared to CECT alone and predict prognosis in PDAC patients after NAT.

Methods

In this retrospective study, 120 PDAC patients (65 women; mean age, 66.7 years [standard deviation, 8.4]) underwent CECT, PET/MRI, and CA 19-9 examinations after NAT between January 2013 and June 2021. Three board-certified radiologists independently rated the overall resectability on a 5

SUBMITTER: Yoo J 

PROVIDER: S-EPMC10201764 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature